Beranda › Leukemia Limfositik Kronis › Ohio › Columbus
Uji klinis Leukemia Limfositik Kronis di Columbus, OH
28 studi untuk Leukemia Limfositik Kronis mencari peserta di lokasi sekitar Columbus (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Menerima pesertaFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- dan 8 lainnya
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- dan 8 lainnya
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Menerima pesertaFase 3
- Study Site 104, Columbus
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Menerima pesertaFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Menerima pesertaFase 2
- The Ohio State University, Columbus
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Menerima pesertaFase 1/2
- Research Site, Columbus
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Menerima pesertaFase 1
- The James Cancer Hospital and Solove Research Institute, Columbus
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Menerima pesertaFase 3
- OSU Comprehensive Cancer Center, Columbus
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
- The Ohio State University Wexner Medical Center, Columbus
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Menerima pesertaFase 1
- The Ohio State University, Columbus
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Menerima pesertaFase 1
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Menerima pesertaFase 1
- The Ohio State University, Columbus
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Menerima pesertaFase 4
- Ohio State University Comprehensive Cancer Center, Columbus
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Menerima pesertaFase 4
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of SGR-1505 in Mature B-Cell Neoplasms
Menerima pesertaFase 1
- The Ohio State University - The James Cancer Hospital, Columbus
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Menerima pesertaFase 2
- The Ohio State University /ID# 230439, Columbus
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Menerima pesertaFase 2
- The Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Menerima pesertaFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Menerima pesertaFase 1
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
HPC Offered for PRESERVE Expansion
Menerima pesertaStudi observasional
- The Ohio State University Medical Center, Columbus
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Menerima pesertaFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Uji klinis Leukemia Limfositik Kronis di kota lain
- Boston, MA31 studi
- Durham, NC27 studi
- Washington, DC22 studi
- Seattle, WA20 studi
- Rochester, MN19 studi
- New York City, NY18 studi
- Houston, TX17 studi
- Baldwin Park, CA16 studi
- Milwaukee, WI15 studi
- Cincinnati, OH14 studi
- Chicago, IL14 studi
- Nashville, TN13 studi
Studi lain di Columbus
- Kanker Paru Non-Sel Kecil56 studi
- Kanker Payudara39 studi
- Kanker Ovarium39 studi
- Kanker (semua jenis)38 studi
- Kanker Paru37 studi
- Leukemia Mieloid Akut35 studi
- Kanker Metastatik27 studi
- Kanker Endometrium25 studi
- Kanker Kolorektal24 studi
- Kanker Prostat24 studi
- Mieloma Multipel24 studi
- Melanoma21 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.